Non-invasive T21 Testing Space Abuzz as Firms Jockey for Share of $1B Market, Battle over IP | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Taking aim at an opportunity that has been estimated at more than $1 billion in the US alone, several firms are using next-generation sequencing and other genomic technologies to break into the diagnostics market for fetal aneuploidy and chromosomal aberrations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.